FDA accepts Roche’s NDA for Xofluza to treat influenza in children

This article was originally published here

The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and

The post FDA accepts Roche’s NDA for Xofluza to treat influenza in children appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply